Marc Bonaca

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Antithrombotics in acute coronary syndromes: updates from the past year
    Marc Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 12:84-99. 2010
  2. doi request reprint Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarct
    Marc P Bonaca
    From TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA M P B, J A G, B M S, S A H, E B, D A M Dartmouth Hitchcock Heart and Vascular Center, Geisel School of Medicine at Dartmouth, Lebanon, NH M A C and Wiener Cardiovascular Institute and Marie Jose and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY J O
    Circulation 133:997-1005. 2016
  3. doi request reprint Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36
    Marc P Bonaca
    Department of Medicine, Brigham and Women s Hospital, Boston, USA
    Eur Heart J Acute Cardiovasc Care 4:431-40. 2015
  4. doi request reprint Pharmacological treatment and current management of peripheral artery disease
    Marc P Bonaca
    From the Vascular Medicine Section, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA
    Circ Res 116:1579-98. 2015
  5. doi request reprint New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2318-26. 2014
  6. doi request reprint Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2309-17. 2014
  7. doi request reprint Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Cardiol Rep 16:536. 2014
  8. doi request reprint Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 127:1522-9, 1529e1-6. 2013
  9. doi request reprint Management of asymptomatic carotid artery stenosis
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 15:252-63. 2013
  10. doi request reprint Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012

Detail Information

Publications19

  1. ncbi request reprint Antithrombotics in acute coronary syndromes: updates from the past year
    Marc Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 12:84-99. 2010
    ..Incremental updates to guideline recommendations from established expert groups will be important in providing guidance...
  2. doi request reprint Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarct
    Marc P Bonaca
    From TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA M P B, J A G, B M S, S A H, E B, D A M Dartmouth Hitchcock Heart and Vascular Center, Geisel School of Medicine at Dartmouth, Lebanon, NH M A C and Wiener Cardiovascular Institute and Marie Jose and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY J O
    Circulation 133:997-1005. 2016
    ..We investigated the causes, sequelae, and predictors of ALI in a contemporary population with symptomatic PAD and whether protease-activated receptor 1 antagonism with vorapaxar reduced ALI overall and by type...
  3. doi request reprint Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36
    Marc P Bonaca
    Department of Medicine, Brigham and Women s Hospital, Boston, USA
    Eur Heart J Acute Cardiovasc Care 4:431-40. 2015
    ..We evaluated the prognostic implications of low-level increases in cardiac troponin I (cTnI) using an investigational single-molecule high-sensitivity assay in patients with acute coronary syndrome (ACS)...
  4. doi request reprint Pharmacological treatment and current management of peripheral artery disease
    Marc P Bonaca
    From the Vascular Medicine Section, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA
    Circ Res 116:1579-98. 2015
    ..Ongoing trials of novel therapies in patients with PAD will further inform pharmacological strategies to reduce both systemic cardiovascular risk and limb-related morbidity. ..
  5. doi request reprint New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2318-26. 2014
    ....
  6. doi request reprint Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 64:2309-17. 2014
    ..Vorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease...
  7. doi request reprint Diagnosis and management of acute aortic syndromes: dissection, intramural hematoma, and penetrating aortic ulcer
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Cardiol Rep 16:536. 2014
    ..The optimal care of patients with acute aortic syndrome requires the cooperation of members of an experienced multidisciplinary team both in the acute and chronic setting. ..
  8. doi request reprint Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 127:1522-9, 1529e1-6. 2013
    ..Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization...
  9. doi request reprint Management of asymptomatic carotid artery stenosis
    Marc P Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 15:252-63. 2013
    ..The most important aspect of the management of asymptomatic carotid artery stenosis is reducing the overall cardiovascular risk of the patient...
  10. doi request reprint Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012
    ..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)...
  11. doi request reprint American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 125:577-83. 2012
    ..The prognostic implications of MI defined in the current era have not been well described...
  12. doi request reprint Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 31:203-10. 2011
    ....
  13. doi request reprint Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I
    Marc Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 55:2118-24. 2010
    ..The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS)...
  14. doi request reprint SCH 530348: a novel oral thrombin receptor antagonist
    Marc P Bonaca
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Future Cardiol 5:435-42. 2009
    ..Two large Phase III clinical outcome trials are currently underway to evaluate the safety and efficacy of SCH 530348 for the management of acute coronary syndromes and the secondary prevention of atherothrombotic events...
  15. ncbi request reprint Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  16. doi request reprint Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  17. doi request reprint Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  18. doi request reprint Antithrombotics in acute coronary syndromes
    Marc P Bonaca
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:969-84. 2009
    ..In addition to reviewing existing agents, we take a look forward at the most promising new antithrombotics currently in late-stage clinical development and their potential role in the context of ACS management...
  19. doi request reprint Defining a role for novel biomarkers in acute coronary syndromes
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 54:1424-31. 2008
    ..Active investigation has brought forward an increasingly large number of novel candidate markers; however, few of these markers have yet to be incorporated into routine clinical use...